Multi-Modal BioInformatics Solution for Ovarian Cancer
|
|
- Jerome Sparks
- 5 years ago
- Views:
Transcription
1 VERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer NASDAQ: VRML l April Vermillion Inc. All Rights Reserved 1
2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of Words such as may, expects, intends, anticipates, believes, estimates, plans, seeks, could, should, continue, will, potential, projects and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements speak only as of the date of this presentation, and the Company does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances after such date except as required by law. Company estimates set forth in this presentation are based on various sources of information and various assumptions and judgments made by the Company, which Company management believes are reasonable. However, the Company cannot assure you that Company estimates are correct, and actual data may materially differ from Company estimates. The forward-looking statements reflect the views of the Company as of the date of this presentation and are subject to certain risks, uncertainties and assumptions, including those described in the section entitled Risk Factors in the Company s Annual Report on Form 10-K for the year ended December 31, 2017 and quarterly report on Form 10-Q for the quarter ended September 30, This presentation is copyright 2019 by Vermillion, Inc. All Rights Reserved. 2
3 Investment Highlights Commercial stage company with ovarian cancer cancer risk assessment test Pipeline of compelling diagnostic bioinformatic solutions FDA approved and incorporated into clinical treatment guidelines Broad managed care coverage CMS reimbursement rate of $897 Intellectual property protecting methods and use Seasoned management team 3
4 Commercial Stage Company Save Lives Replace Standard of Care Payers * Guidelines Bioinformatic Tools + Current Standard Care Strong IP and FDA-Cleared Science Foundation in place for OVA 1 to become the new Standard of Care Payer Coverage: 5 out of 10 lives covered in U.S. 4
5 The Size of the Pelvic Pain and Mass Market TAM Cost $ 18.5M 500K- 1M $22B $0.8B Pelvic Masses + (Endo + PCOS+ Func. Cysts) Pelvic Masses (Benign masses, cancer, non-gyn mass) Technology Solutions Today None None VRML Portfolio POC Complete (DXA II) Watch + Wait (DXA1) 200K Pelvic Masses to Surgery Ova1+ (OVA1, Overa) Ova1+ (OVA1, Overa) 22K $5.2B Ovarian Cancer CA125 Recurrence Monitoring Portfolio Funnel Ovarian 15K Cancer Deaths Total: 20M $28B 5
6 Paradigm Shift- Single Modality vs. Multi-modality Approach Protein Biomarkers Cell Free DNA OVA 360 FDA Cleared Algorithms - Systemic Dx OVA360 = - Focused Dx - Family Hx / Genetics - Patient Reported Data (Symptom Index) Clinical Assessment + Symptom Index + Imaging Hereditary Breast and Ovarian Cancer (HBOC) Genetics 6
7 Ovarian Cancer: A Severe Clinical Problem - > 60% of Ovarian Cancers are diagnosed at late stage - > 50% mortality rate (only gender specific disease with greater than a 50% mortality rate) - Mortality has not changed in 30 years Presentation Stage and 5-Year Survival Rate Presentation Stage Incidence 5-year survival rate (Stage I) Localized 15% 93% 4 (Stage II) Regional 20% 73% (Stage III) Distant 60% 29% (Stage IV) Unstaged 6% 25% NEED A BETTER SOLUTION 7
8 The Why: Current Assessment Tools are Inadequate CLINICAL ASSESSMENT: PHYSICAL EXAM AND ULTRASOUND Analysis of results is subjective Results are specialist-dependent BLOOD TUMOR MARKER: OFF-LABEL USE OF CA-125 (1981) / ALTERNATIVE TECHNOLOGY ROMA (2011) Both approaches have high rate of false negatives Especially in premenopausal and early stage patients TISSUE ANALYSIS: PREOPERATIVE BIOPSY- NOT MEDICALLY APPROPRIATE Cannot biopsy pelvic cavity Possible spread of tumor intra-abdominally if biopsy ruptures mass 8
9 Our Solution = OVA1 + OVERA (OVA1 +) For the detection of Ovarian Cancer Risk in Women with Pelvic Masses Launch 2010 OVA1 evaluates the levels of five ovarian cancer-associated markers in the blood Levels combined into a single ovarian cancer risk score. Multi-variate Index Assay (MIA) in ACOG Guidelines Positive NCCN and SGO position statements Launch Q Overa incorporates 2 new markers Global Platform Specificity + 9
10 Improved Specificity OVA1 + - Ova1/Overa Reflex Offering- Launched Q Low Risk ACOG Endorsed Intermediate Risk Reflex to: ACOG Endorsed Elevated Risk Premenopausal 2 : Low Risk < 5.0; Intermediate ; Elevated Risk > 7.0 Postmenopausal 2 : Low Risk < 4.4; Intermediate ; Elevated Risk > 6.5 OVA1 1 (95%CI) Overa 1 (95% CI) OVA1 + (95% CI) % Diff OVA1 vs OVA1+ Sensitivity 92% 91% 88% -4% Specificity 54% 69% > 30% improvement in specificity 1. Coleman RL, Herzog TJ, Chan DW, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol 2016;215:82.e Reference Ranges established by ASPiRA Labs, Austin Tx. 72% 33% 10
11 Improved Early Stage Detection: OVA1 Plus vs Standard of Care in Stage I + II Patients 94% Improvement in Rate of Cancer Detected with OVA1 11
12 Non-white women, and African-American women in particular, display significantly lower CA125 values compared to Caucasian women This disparity is found in healthy women, women at high risk for ovarian cancer, and women with ovarian cancer (Caucasian) 1645 (Non-white) 582 (Caucasian) 35 (Non-white) (Caucasian) 89 (African-American) 1-4: 1. Pauler, D., et al. Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. Cancer Epidemiology, Biomarkers & Prevention, 10: , 2001, 2. Skates, S., at al. Large Prospective Study of Ovarian Cancer Screening in High-risk Women: CA125 Cut-point Defined by Menopausal Status. Cancer Prevention Research, 4(9), , 2011, 3. Cramer, D., et al. Correlates of the pre-operative level of CA125 at presentation of ovarian cancer. Gynecologic Oncology, 119(3), , 2010., 4. Babic, A., at al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes & Control : CCC, 28(5), , (Premenopausal, non-african-american) 68 (Premenopausal, African American) 1604 (Postmenopausal, non-african-american) 52 (Postmenopausal, African-American) 12
13 High Level Internal Data from ASPiRA LABS OVA1 Superiority over CA125 in African American Women OVA1 CA125 Sens (%) Spec (%) PPV NPV Caucasian (N=873) African American (N=156) Caucasian (N=873) African American (N=156) CA125 has an unacceptable sensitivity for cancer detection in African American women Abstract accepted and presented at Mid Atlantic Gynecologic Oncology Society (MAGOS) in October 2018 Abstract accepted at American Association for Cancer Research (AACR) Manuscript submitted for publication- pending acceptance (OVA1 shows an acceptable sensitivity for cancer detection in African American women, cutoff adjustment is in process for pre and post menopausal women, to achieve the 90% sensitivity obtained for Caucasian women 5) 5: ASPiRA Labs Data on File, Combined OVA1 and OVA500 studies Vermillion Inc. All Rights Reserved 13
14 Summary of OVA1 + Sensitivity Across All Stages* CA125 Stage I X Stage II X Stage III Stage IV Sensitivity Across Menopausal Status* Pre-menopausal X Post-menopausal Sensitivity Across Histological Subtypes* Epithelial ovarian cancer Non-epithelial cancer X Low malignant potential X Metastatic Other gyn cancer X Sensitivity Across All Ethnicities* Caucasian and African American X Ovarian Cancer still remains a diagnostic dilemma for GYN and Primary Care physicians making OVA1 + more clinically relevant For High Risk: o Early detection and appropriate referral to Gyn Oncologists give patients a survival benefit and is proven to be cost-effective For Low Risk: o The NPV of OVA1 + will ensure the correct treatment plan, and reassure both the patient and the Gyn provider when planning surgery OVA1 + truly changes how providers treat patients Vermillion Inc. All Rights Reserved 14
15 Commercialization Strategy Direct to Gynecologists - Centralized Testing 20 Sales Territories Calling on Gynecologists to drive volume Calling on and Gynecologic Oncologists to increase awareness Tests performed in our Lab Entrepreneurial Commercial Force Sales team has average of 15 years experience in genetics, diagnostic lab and women s health space Strong relationships with large Ob Gyn practices/physicians in target markets Top performers in companies with disruptive technology successful growing volume from ground level >75% of hires were involved in the initial rollout of NIPT 15
16 Commercial Investment S A L E S T E A M Payers Investment in Commercial 2.5X year on year PAMA Rate Evicore Live Launch: Decentralized Platform OVA1+ 16
17 Commercialization Strategy- US + Ex US Decentralized- Performed in Local Setting Testing Performed in Hospital Systems/Large Gyn Super Group Increase POC (Point of Care) Test performed locally with access to Vermillion risk assessment software via web service OVA1 performed on existing Platform Roche Cobas installed base of over 10K units globally Algorithm Warehouse OvaCalc Cloud based bioinformatics platform Technology Transfer Customer Vermillion Data Repository 17
18 International - Commercial Strategy Long Term Both OVA1/Overa have CE Mark Philippines Large prospective study in process International via Platform/Web Service Israel Q Coverage received in Israel by CLALIT 2 nd largest integrated delivery network in the world CLALIT (#1 Payer, 50% pop) Study in process to validate Overa & OVA1 on local population 18
19 Market Access Covered Lives Cigna added in January 2019 Coverage: Patient Lives In Millions 167M Cigna added Ova1 to its National Preferred Coverage List in January 2019 Goal: Targeted Growth with Positive Medical Policy Decisions 51% of the Population Now Under Positive Coverage 1/
20 Reimbursement Rates have increased steadily Weighted Average Ova1 Price Per Test TARGET GOAL PAMA Price set for OVA1 PAMA Rate = $897 CPT Code
21 Historical Cash Utilization Q Disciplined capital deployment PayersCash to support commercialization plans Q1 '17 Q2 '17 Q3 '17 Q4 '17 Q1 '18 Q2 '18 Q3 '18 Q4 '18 Beginning Cash Balance $5,242 $7,897 $6,028 $7,700 $5,539 $3,100 $14,134 $11,760 Financing Activities $5,255 ($129) $3,581 ($5) $0 $13,529 $0 $0 Cash Utilization ($2,600) ($1,740) ($1,909) ($2,156) ($2,439) ($2,495) ($2,374) ($2,400) Ending Cash Balance $7,897 $6,028 $7,700 $5,539 $3,100 $14,134 $11,760 $9,360 Additional existing sources of financing: State of CT Forgivable Loan $2M (Contingent on achieving milestones) Callable Warrants $5M (Contingent on stock price performance) 21
22 Portfolio Opportunity Size US + Ex-US Overall Total: $2.2B - $4.4B US $90M-$269M EX-US $100M-$300M US $440M-$880M EX-US $500M-$1.0B US $1.2B-$2.4B EX-US $1.0B-2.0B US K TAM EX-US 1M-3M TAM Guided referral US 250K-1M TAM EX-US 2.5M-10M TAM Rule out; watchful waiting, surgical choice, disease progression, high risk BRCA, recurrence monitoring US>1M TAM EX-US > 10M TAM Endometriosis, polycystic ovary syndrome 22
23 2019 Key Catalysts Payer Expansion Bio-informatics Platform- Beyond Proteins Portfolio Expansion- Watch and Wait + ( M) OVA1+ vs Standard of Care Publications/Tools Ca125 Disparity Data Published/ Symptom Index Tool Live Commercial Team Expansion Complete Decentralized Partnership Expansion Pelvic Mass Portfolio Expansion 23
24 Strategy: Built For Growth Strategic Strengths and Capabilities MYGN GHDX EXAS VRML FDA-cleared product X HBOC X Unique Category 1 CPT code (AMA) Medicare Coverage/Gap Fill Pricing IVD Kit X X X CLIA lab for LDTs Multi-modal Predictive predictive Analytics analysis X X X Proprietary Disease Registry/Samples Leading Peer-reviewed Publications Strong Outreach: KOLs/Advocacy 24
25 Investment Summary Commercial stage company with ovarian cancer risk assessment test Recently Expanded Sales Team Broad managed care coverage CMS reimbursement rate of $897 Pipeline of compelling diagnostic bioinformatic solutions Seasoned management team 25
26 Appendix 26
27 Majority of Pelvic Masses Are Benign A Low False Negative Rate Is Critical For Patient Care Early Stage Sensitivity (%) Specificity (%) Early Stage False Negative Rate(%) False Positive Rate(%) Clinical Assessment (CA) Standalone Risk Stratification Ultrasound alone CA125 alone ROMA (Ca125 & HE4) OVA1 alone Overa alone OVA1 +* Demonstration of Improvement - Reducing False Negatives by Over 50% 1. Longoria, TC et al. AJOG Jan 2014, 210(1,): 78.e1-78.e9 2. Pavlik EJ, van Nagell JR Jr. Womens Health (Lond) Jan;9(1): Partheen K, Kristjansdottir B, Sundfeldt K. J Gynecol Oncol. 2011;22(4): Chudecka-Glaz, A et al. J Mol Biomark Diagn. 2013, S4: Bristow, RE et al. Gynecol Cncol. 2013, 128: Coleman RL, Herzog TJ, Chan DW, et al. Am J Obstet Gynecol 2016;215:82.e ASPiRA Labs Data on File, Combined OVA1 and OVA500 studies. *Internal data on file Average of 4 trials in study
28 Better Science & Demonstrated Lower Cost OVA1 +: better science than CA-125 Use of OVA1 + vs CA-125 lowers total costs while improving care and addressing racial disparity Our study findings suggest that OVA1 testing due to its increased sensitivity and NPV may result in savings for payers of $0.05 PMPM by enabling physicians to better manage patients in the appropriate setting of care 1 24-month average reimbursement for early- and late-stage cancer Cancer Stage Commercial Insurance Reimbursement Premenopausal Women Postmenopausal Women Early-stage Cancer $35,754 $37,195 Late-stage Cancer $224,922 $197,757 * Reimbursement rates are static between current and future states If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent, Dr. Robert E. Bristow, Director of Gynecologic Oncology, University of California 1 Brodsky B.S., Owens G.M., Scotti, D.J., et al. AHDB. 2017:10(7): Vermillion Inc. All Rights Reserved 28
29 Trusted Solution: Care Pathway Guidelines Publications Drive Standard of Care Published Evidence OVAI (MIA) Guidelines / Position Statements * Ueland, et al Obstetrics and Gynecology, 2011 Bristow, et al. Gynecologic Oncology, 2013 Am J Gynecol, 2013 ACOG Practice Bulletin Number 174, November 2016, page 10 Longoria, et al. Am J Obstet Gynecol, 2013 Goodrich, et al. Am J Obstet Gynecol, 2015 Forde, et al. Curr Med Res Opin, 2015 National Comprehensive Cancer Network Guidelines, Version 5, 2017 Updated Feb 2, 2018 Coleman, et al. Am J Obstet Gynecol, 2016 Eskander, et al. Am J Obstet Gynecol, 2016 Urban, et al. Int. J Gynecol Cancer, 2017 Brodsky, et al. Am Health & Drug Benefits, 2017 Society of Gynecologic Oncology Position Statements Issued 2011 Updated 2013 * In 100% of all Key Guidelines 29
30 Care Pathway Guidelines Converted to the Gyn Practice Best Care pathway- LEVEL A + LEVEL B ACOG Pelvic Mass Detected on Ultrasound (ACOG Level A) Clearly Benign Simple appearance, smooth, thin walls, absence of solid components or septations, lack of internal blood flow on color Doppler. Generally <10cm, but even above 10cm if cyst is simple risk of malignancy is 1%. Watchful waiting management of symptoms Not Clear Everything else (3-10cm) not thin walled, > 1 septation, small nodules. With OVA1 you get a clear picture when managing adnexal masses Elevated Risk Of Malignancy Refer GynOnc GynOnc Consults ACOG Level B Low Risk Of Malignancy OB / GYN Treats No Further Imaging Included in ACOG Adnexal Mass Management Guidelines Clearly Malignant Cyst. 10cm, papillary or solid components, irregularity, presence of ascites high color Doppler flow. Get CA-125 and refer to Gyn Onc immediately 30
31 Protected Solutions: Strong IP Intellectual Property: Strong Portfolio Granted Pending Family USA Ex US Total USA Ex US Total Issued patents covering various ovarian cancer biomarkers Pending patent applications covering OVA1 and Overa products Algorithm kept as trade secret 31
VERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer
VERMILLION Multi-Modal BioInformatics Solution for Ovarian Cancer NASDAQ: VRML l August 2018 2018 Vermillion Inc. All Rights Reserved 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking
More informationVERMILLION. Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes. NASDAQ: VRML NOVEMBER Vermillion Inc. All Rights Reserved
VERMILLION Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes NASDAQ: VRML NOVEMBER 2017 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the
More informationDiagnostic Bioinformatic Solutions to Change Gynecologic Outcomes
Diagnostic Bioinformatic Solutions to Change Gynecologic Outcomes NASDAQ: VRML JANUARY 2017 1 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, as defined in the Private
More informationAUGUST Vermillion Inc. All Rights Reserved
z AUGUST 2017 2017 Vermillion Inc. All Rights Reserved Forward Looking Statements This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995.
More informationAdnexal Mass Management: Risk Stratification and Management Practice for Best Patient Outcomes
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAdnexal Masses in Menopausal Women Surgery or Surveillance?
Adnexal Masses in Menopausal Women Surgery or Surveillance? FREDTALK IDEASWORTHSPREADING Disclosure I am a member of Vermillion s Speakers Bureau I am NOT a paid consultant for Vermillion Inc. nor do I
More informationAdnexal Masses in Menopausal Women
Adnexal Masses in Menopausal Women Surgery or Surveillance? Disclosure Frederick R. Ueland, MD Professor and Director Division of Gynecologic Oncology University of Kentucky I have no financial disclosures
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationMULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER
MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationProtocol. Multimarker Serum Testing Related to Ovarian Cancer
Protocol Multimarker Serum Testing Related to Ovarian Cancer (20462) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/11, 01/12, 01/13, 01/14, 01/15,
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationThis policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.
Medical Coverage Policy Multimarker Serum Testing Related to Ovarian Cancer EFFECTIVE DATE: 10 01 2015 POLICY LAST UPDATED: 04 17 2018 OVERVIEW This policy documents the coverage determination for Multimarker
More informationTriage of Ovarian Masses. Andreas Obermair Brisbane
Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led
More informationProteomics-Based Testing for the Evaluation of Ovarian (Adnexal) Masses
Proteomics-Based Testing for the Evaluation of Ovarian (Adnexal) Masses Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationPublic Statement: Medical Policy Statement: Limits: Medical Policy Title: OVA1, Detection of Ovarian Cancer. ARBenefits Approval: 10/26/2011
ARBenefits Approval: 10/26/2011 Effective Date: 01/01/2012 Revision Date: 08/21/2013 Medical Policy Title: OVA1, Detection of Ovarian Cancer Document: ARB0295:02 Administered by: Public Statement: The
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationProteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses
MP 2.04.50 Proteomics-based Testing for the Evaluation of Ovarian (Adnexal) Masses Medical Policy Section Medicine Issue 12:2013 Subsection Original Policy Date 12:2013 Last Review Status/Date Reviewed
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationCorporate Presentation. June 2017
v Corporate Presentation June 2017 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
More informationCorporate Presentation. October 2012
Corporate Presentation October 2012 Forward-Looking Statements The following information contains certain forward-looking statements relating to the company s business, which can be identified by the use
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationCorporate Presentation. First Quarter 2018
Corporate Presentation First Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationThe New England Journal of Medicine. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer
The New England Journal of Medicine A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer May 18, 2015 Forward-Looking Statements Various remarks that we make on this call that are
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationCorporate Presentation. Second Quarter 2018
Corporate Presentation Second Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationSCREENING FOR OVARIAN CANCER DR MACİT ARVAS
SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were
More informationDiagnostics for the early detection and prevention of colorectal cancer.
Diagnostics for the early detection and prevention of colorectal cancer. Company Presentation May 2013 Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationMultimarker Serum Testing Related to Ovarian Cancer
Multimarker Serum Testing Related to Ovarian Cancer Policy Number: 2.04.62 Last Review: 2/2018 Origination: 9/2010 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not
More informationOvarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)
Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics. William Annett Chief Executive Officer
Liquid Biopsies Next Generation Cancer Molecular Diagnostics William Annett Chief Executive Officer June 2016 Forward Looking Statements Statements pertaining to future financial and/or operating results,
More informationMolecular Cytology That Transforms Patient Care. William Blair 35 th Annual Growth Stock Conference June 9, 2015
Molecular Cytology That Transforms Patient Care William Blair 35 th Annual Growth Stock Conference June 9, 2015 Forward-Looking Statements Various remarks that we make in this presentation that are not
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Company Presentation Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This presentation contains forward-looking
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationMultimarker and Proteomics-based Serum Testing Related to Ovarian Cancer
Medical Policy Manual Laboratory, Policy No. 60 Multimarker and Proteomics-based Serum Testing Related to Ovarian Cancer Next Review: December 2018 Last Review: January 2018 Effective: February 1, 2018
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics William Annett Chief Executive Officer. October 2016
Liquid Biopsies Next Generation Cancer Molecular Diagnostics William Annett Chief Executive Officer October 2016 Forward Looking Statements Statements pertaining to future financial and/or operating results,
More informationGynaecological cancers. Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist
Gynaecological cancers Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist Gynaecological cancers Why do we need 2 week wait? Early/timely diagnosis of cancer Possibly less invasive treatment and
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More information21 st Annual Needham Growth Conference
21 st Annual Needham Growth Conference Title January 15, 2019 Bonnie Anderson Chairman and Chief Executive Officer Forward-Looking Statements This presentation contains forward-looking statements, within
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAsk the Experts Obstetrics & Gynecology
1 Management of the Adnexal Mass James H. Liu, MD, and Kristine M. Zanotti, MD June 2011 Volume 117 Issue 6 Pages 1413 28 Click Here to Read the Full Article Questions written by: Rini Banerjee Ratan,
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationRESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.1949 RESEARCH ARTICLE Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationHuman epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts
Human epididymal protein 4 The role of HE4 in the management of patients presenting with pelvic mass Publication abstracts Ovarian cancer is diagnosed annually in more than 200,000 women worldwide, with
More informationGuardant Health Investor Presentation. January 2019
Guardant Health Investor Presentation January 2019 Safe harbor statement This presentation contains forward-looking statements, which are statements related to future events that by their nature address
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCorporate Presentation. Fourth Quarter 2018
Corporate Presentation Fourth Quarter 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationLiquid Biopsies. Advancing cancer diagnosis. William Annett Chief Executive Officer
Liquid Biopsies Advancing cancer diagnosis William Annett Chief Executive Officer June 2017 Forward Looking Statements Statements pertaining to future financial and/or operating results, future research,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCorporate Presentation. August 2016
v Corporate Presentation August 2016 Safe harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More informationItamar Medical. December Investors Presentation.
Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationWhen the question is genetics, the answer is Invitae Invitae Corporation. All Rights Reserved. 1
When the question is genetics, the answer is Invitae. L A D E N B U R G T H A L M A N N 2 0 1 8 H E A LT H C A R E C O N F E R E N C E S E A N G E O R G E, C H I E F E X E C U T I V E O F F I C E R 2018
More informationCorporate Medical Policy
Corporate Medical Policy Serum Biomarker Human Epididymis Protein 4 (HE4) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: serum_biomarker_human_epididymis_protein_4_(he4) 1/2010
More informationDiagnostics guidance Published: 15 November 2017 nice.org.uk/guidance/dg31
Tests in secondary care to identify people at high risk of ovarian cancer Diagnostics guidance Published: 15 November 2017 nice.org.uk/guidance/dg31 NICE 2017. All rights reserved. Subject to Notice of
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationWho Pays for Personalized Medicine? A Conversation With Industry Insiders. July 15, 2010 Garden Court Hotel, Palo Alto
Who Pays for Personalized Medicine? A Conversation With Industry Insiders July 15, 2010 Garden Court Hotel, Palo Alto Speakers Aidan Toombs, Attorney, Crescendo Bioscience Judy Waltz, Partner and Co-Chair,
More informationOVARIAN CANCER Updates in Screening, Early Detection and Prevention
UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationIOTA and Models for Screening for Ovarian Cancer
IOTA and Models for Screening for Ovarian Cancer Hennie Botha MARCH 2017 T H IG PY R O C F O SP EA KE R Silent Killer to Whispering Disease Listening to your body.. new, persistent, and increases in severity
More informationFocus on... Ovarian cancer. HE4 & ROMA score
Focus on... Ovarian cancer HE4 & ROMA score Ovarian cancer in the world* Accounting for around 4% of all cancers diagnosed in women The estimated World age-standardised incidence rate for the more developed
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationH.C. Wainwright Global Investment Conference September 6, 2018 OTC: PRED predtechgroup.com
H.C. Wainwright Global Investment Conference September 6, 2018 OTC: PRED predtechgroup.com Safe Harbor This presentation contains forward-looking statements. Statements that are not a description of historical
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) March 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More information